ID: ALA3322935

Max Phase: Preclinical

Molecular Formula: C25H22N4O6

Molecular Weight: 474.47

Molecule Type: Small molecule

Representations

Canonical SMILES:  COC(=O)c1cccc(NC(=O)c2cc(-n3cc(-c4cc(OC)cc(OC)c4)nn3)ccc2O)c1

Standard InChI:  InChI=1S/C25H22N4O6/c1-33-19-10-16(11-20(13-19)34-2)22-14-29(28-27-22)18-7-8-23(30)21(12-18)24(31)26-17-6-4-5-15(9-17)25(32)35-3/h4-14,30H,1-3H3,(H,26,31)

Standard InChI Key:  NAEAGLUMQZLQJC-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 474.47

Molecular Weight (Monoisotopic): 474.1539

AlogP: 3.70

#Rotatable Bonds: 7

Polar Surface Area: 124.80

Molecular Species: NEUTRAL

HBA: 9

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 10

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 8.34

CX Basic pKa:

CX LogP: 4.19

CX LogD: 4.14

Aromatic Rings: 4

Heavy Atoms: 35

QED Weighted: 0.39

Np Likeness Score: -1.36

References

1. Song D, Park Y, Yoon J, Aman W, Hah JM, Ryu JS..  (2014)  Click approach to the discovery of 1,2,3-triazolylsalicylamides as potent Aurora kinase inhibitors.,  22  (17): [PMID:25042560] [10.1016/j.bmc.2014.06.047]

2. Jeong Y, Lee J, Ryu JS..  (2016)  Design, synthesis, and evaluation of hinge-binder tethered 1,2,3-triazolylsalicylamide derivatives as Aurora kinase inhibitors.,  24  (9): [PMID:27041399] [10.1016/j.bmc.2016.03.042]

Source

Source(1):

• Scientific Literature